Ronald C. DeConti

9.2k total citations · 2 hit papers
92 papers, 7.1k citations indexed

About

Ronald C. DeConti is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ronald C. DeConti has authored 92 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 25 papers in Molecular Biology and 15 papers in Immunology. Recurrent topics in Ronald C. DeConti's work include Cutaneous Melanoma Detection and Management (16 papers), Melanoma and MAPK Pathways (14 papers) and Head and Neck Cancer Studies (14 papers). Ronald C. DeConti is often cited by papers focused on Cutaneous Melanoma Detection and Management (16 papers), Melanoma and MAPK Pathways (14 papers) and Head and Neck Cancer Studies (14 papers). Ronald C. DeConti collaborates with scholars based in United States, Canada and United Kingdom. Ronald C. DeConti's co-authors include Richard Heller, David Schoenfeld, William A. Creasey, Joseph R. Bertino, Arlene A. Forastiere, Douglas S. Reintgen, Adil Daud, Jane L. Messina, Robert Lange and Claudia G. Berman and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Ronald C. DeConti

91 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

2008 503 citations Adil Daud, Ronald C. DeConti et al. Journal of Clinical Oncology profile →
Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).

1973 362 citations Ronald C. DeConti et al. profile →

Peers

Countries citing papers authored by Ronald C. DeConti

Since Specialization

Citations

This map shows the geographic impact of Ronald C. DeConti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald C. DeConti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald C. DeConti more than expected).

Fields of papers citing papers by Ronald C. DeConti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald C. DeConti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald C. DeConti. The network helps show where Ronald C. DeConti may publish in the future.

Co-authorship network of co-authors of Ronald C. DeConti

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald C. DeConti. A scholar is included among the top collaborators of Ronald C. DeConti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald C. DeConti. Ronald C. DeConti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma 2016 ·Melanoma Research ·Sarah Sloot, Jonathan S. Zager, Ragini R. Kudchadkar, Jane L. Messina, (unknown), Ricardo J. Gonzalez, Ronald C. DeConti, Leslie M. Turner, (unknown), Keiran S.M. Smalley, Jeffrey S. Weber, Vernon K. Sondak, Geoffrey T. Gibney	20
2	Chemotherapy of Squamous Cell Carcinoma of the Skin 2012 ·Seminars in Oncology ·Ronald C. DeConti	36
3	A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck 2011 ·Cancer ·Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, Rita Axelrod, Ronald C. DeConti, Arlene A. Forastiere	59
4	Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma 2011 ·British Journal of Cancer ·Alain P. Algazi, Jeffrey S. Weber, Stephanie Andrews, P. Urbas, Pamela N. Münster, Ronald C. DeConti, Justin H. Hwang, Vernon K. Sondak, Jane L. Messina, Timothy H. McCalmont, Adil Daud	33
5	Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma 2010 ·Cancer Chemotherapy and Pharmacology ·Adil Daud, Christine Xu, Wen‐Jen Hwu, P. Urbas, Stephanie Andrews, Nicholas E. Papadopoulos, Leslie Carstensen Floren, Antoine Yver, Ronald C. DeConti, Vernon K. Sondak	17
6	Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma 2010 ·British Journal of Cancer ·Ronald C. DeConti, Alain P. Algazi, Stephanie Andrews, P. Urbas, (unknown), Detlef Stoeckigt, Leslie Carstensen Floren, Justin H. Hwang, Jeffrey S. Weber, Vernon K. Sondak, Adil Daud	12
7	A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin) 2010 ·American Journal of Clinical Oncology ·Wolfram E. Samlowski, James Moon, Ralph J. Tuthill, Michael C. Heinrich, (unknown), (unknown), Ronald C. DeConti, John A. Thompson, (unknown), Lawrence E. Flaherty, Vernon K. Sondak	63
8	Systemic Treatments for Merkel Cell Carcinoma 2010 ·Current Problems in Cancer ·Ragini R. Kudchadkar, Ronald C. DeConti	3
9	Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma 2010 ·Annals of Oncology ·Agop Y. Bedikian, Ronald C. DeConti, Robert M. Conry, Sanjiv S. Agarwala, Nikolaos G. Papadopoulos, (unknown), Marc S. Ernstoff	92
10	Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma 2010 ·Journal of Immunotherapy ·Steven E. Finkelstein, Timothy S. Carey, Ingo Fricke, Daohai Yu, (unknown), (unknown), Mary Dunn, P. Urbas, Adil Daud, Ronald C. DeConti, Scott Antonia, Dmitry I. Gabrilovich, Mayer Fishman	31
11	Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial 2009 ·Clinical Cancer Research ·Adil Daud, Jana L. Dawson, Ronald C. DeConti, Elona Biçaku, Douglas C. Marchion, (unknown), (unknown), Richard M. Lush, Anthony Neuger, Daniel M. Sullivan, Pamela N. Münster	78
12	Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma breakdown → 2008 ·Journal of Clinical Oncology ·Adil Daud, Ronald C. DeConti, Stephanie Andrews, P. Urbas, Adam I. Riker, Vernon K. Sondak, Pamela N. Münster, Daniel M. Sullivan, Kenneth E. Ugen, Jane L. Messina, Richard Heller	503
13	Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy 1998 ·British Journal of Cancer ·LM Mir, (unknown), Gregor Serša, Justin Teissié, C. Domenge, Damijan Miklavčič, (unknown), Stéphane Orlowski, Reintgen Ds, Z Rudolf, (unknown), R. A. Gilbert, Marie‐Pierre Rols, Jean Belehradek, J.M. Bachaud, Ronald C. DeConti, Borut Štabuc, Maja Čemažar, P Coninx, Richard Heller	356
14	Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes 1998 ·Annals of Surgical Oncology ·Emmanuella Joseph, Andrea Brobeil, Frank Glass, (unknown), Jane L. Messina, Ronald C. DeConti, (unknown), David P. Rapaport, Claudia G. Berman, N A Fenske, Douglas S. Reintgen	87
15	Multiple primary melanomas: Implications for screening and follow-up programs for melanoma 1997 ·Annals of Surgical Oncology ·Andrea Brobeil, David P. Rapaport, Karen Wells, C. Wayne Cruse, Frank Glass, Neil A. Fenske, John J. Albertini, (unknown), Jane L. Messina, Ronald C. DeConti, Claudia G. Berman, Alan R. Shons, Alan Cantor, Douglas S. Reintgen	63
16	Comparison of techniques in locating sentinel nodes in patients with malignant melanoma 1997 ·Melanoma Research ·David P. Rapaport, (unknown), (unknown), L. Frank Glass, C. Wayne Cruse, Karen Wells, Ronald C. DeConti, Claudia G. Berman, Jane L. Messina, Neil A. Fenske, D Reintgen	1
17	Concurrent 72-Hour Continuous Infusion of Etoposide and Cisplatin in Metastatic Breast Cancer 1996 ·American Journal of Clinical Oncology ·Scot C. Remick, (unknown), (unknown), Jonathan Sporn, (unknown), (unknown), Ronald C. DeConti, John Horton, John C. Ruckdeschel, Gregory Harper	11
18	Intraoperative Radiolymphoscintigraphy Improves Sentinel Lymph Node Identification for Patients with Melanoma 1996 ·Annals of Surgery ·John J. Albertini, C. Wayne Cruse, David P. Rapaport, Karen Wells, Merrick I. Ross, Ronald C. DeConti, Claudia G. Berman, (unknown), (unknown), Gary H. Lyman, Frank Glass, N A Fenske, Douglas S. Reintgen	424
19	Detection of Submicroscopic Lymph Node Metastases with Polymerase Chain Reaction in Patients with Malignant Melanoma 1994 ·Annals of Surgery ·Xiangning Wang, Richard Heller, (unknown), C. Wayne Cruse, Frank Glass, Neil A. Fenske, Claudia G. Berman, (unknown), (unknown), Karen Wells, Ronald C. DeConti, Lynn C. Moscinski, (unknown), Chris Puleo, Douglas S. Reintgen	220
20	A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer 1991 ·Cancer ·(unknown), John C. Ruckdeschel, James H. Keller, Gary H. Lyman, (unknown), John S. Macdonald, Ronald C. DeConti, Jeannette Lee, Q. Scott Ringenberg, William P. Patterson, Hillard M. Lazarus, Jacob J. Lokich	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact